Losartan Dose Adjustments for South Asian Patients
Evidence-based guide to losartan dosing in South Asian populations, covering CYP2C9 pharmacogenomics, cardiovascular risk thresholds, and clinical monitoring strategies.
Read clinical reviewTopic Hub
7 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 7 of 7 clinical reviews.
Evidence-based guide to losartan dosing in South Asian populations, covering CYP2C9 pharmacogenomics, cardiovascular risk thresholds, and clinical monitoring strategies.
Read clinical reviewEast Asian patients metabolize losartan differently due to CYP2C9 and CYP3A4 variation, higher rates of poor-metabolizer phenotypes, and lower average body weight. This guide covers evidence-based dose adjustments, pharmacogenomic considerations, and monitoring targets for East Asian patients on losartan.
Read clinical reviewA clinician-reviewed guide to how East Asian ancestry affects losartan pharmacokinetics, pharmacodynamics, dosing, and safety, including CYP2C9 poor-metabolizer rates, ethnicity-stratified trial data, and evidence-based prescribing adjustments.
Read clinical reviewA clinician-reviewed guide to losartan dosing in Hispanic and Latino patients, covering CYP2C9 pharmacogenomics, diabetes-related considerations, LIFE trial subgroup data, and PharmGKB-based prescribing guidance.
Read clinical reviewEvidence-based guide to losartan dosing, pharmacogenomics, and clinical outcomes in Black and African ancestry patients, including LIFE trial subgroup data, CYP2C9 pharmacogenomics, and JNC/ACC/AHA guideline context.
Read clinical reviewA clinical deep-dive into how losartan's pharmacokinetics, pharmacogenomics, and real-world safety profile may differ in Hispanic and Latino patients, with evidence from ethnicity-stratified trial data and population genetics research.
Read clinical reviewA clinical review of losartan pharmacogenomics, ethnicity-stratified trial data, and dosing considerations specific to Hispanic and Latino patients with hypertension or diabetic nephropathy.
Read clinical review